ANIP NASDAQ
ANI Pharmaceuticals, Inc.
1W: -2.5%
1M: -1.2%
3M: -15.1%
YTD: -8.0%
1Y: -20.0%
3Y: +19.8%
5Y: +125.9%
$72.18
-0.78 (-1.07%)
Weekly Expected Move ±4.3%
$66
$69
$72
$75
$78
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (100)
Implied Volatility Surging for ANI Pharmaceuticals Stock Options
183,066 Shares of ANI Pharmaceuticals, Inc. $ANIP Acquired by Bank of America Corp DE
Amundi Boosts Stock Position in ANI Pharmaceuticals, Inc. $ANIP
Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
ANI Pharmaceuticals (ANIP) Q2 2026 Earnings Call Transcript
Amundi Has $352,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP
ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut
ANI Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates
ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates
Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline
TG Therapeutics (TGTX) Misses Q2 Earnings Estimates
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Analysts
Bessemer Group Inc. Acquires 19,800 Shares of ANI Pharmaceuticals, Inc. $ANIP
ANI Pharmaceuticals' CFO Sold $285,000 in Stock After a 32% Run
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
Ani (ANIP) Q1 2026 Earnings Call Transcript
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
Zacks.com featured highlights include ANI, Cummins and Seadrill
ANI Pharmaceuticals, Inc. (ANIP): A Small Cap Value Stock Capitalizing on Generic Drugs Opportunities
3 Stocks Showing Powerful Earnings Acceleration This May
ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
ANI Pharmaceuticals Non-GAAP EPS of $2.05 beats by $0.75, revenue of $237.5M beats by $29.87M
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
Here are the major earnings before the open Friday
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Cheniere Energy to Report Q1 Earnings: What's in the Offing?
ANI Pharmaceuticals (ANIP) is a Top-Ranked Growth Stock: Should You Buy?
ImmunityBio to Report Q1 Earnings: What's in the Cards?
BioXcel Therapeutics, Inc. (BTAI) Expected to Beat Earnings Estimates: Should You Buy?
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?
Guardian Pharmacy Services to Report Q1 Earnings: What's in the Cards?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Zacks.com featured highlights include Mirion Technologies, Intuit and ANI Pharmaceuticals
NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLA
Zacks.com featured highlights include Mirion Technologies, Intuit and ANI Pharmaceuticals
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
3 Top Stocks With Accelerating Earnings and Solid Upside Ahead
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout
Why ANI (ANIP) is Poised to Beat Earnings Estimates Again
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
ANI Pharmaceuticals (NASDAQ:ANIP) Stock Passes Below 200-Day Moving Average – Here’s Why
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock
KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data
ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target?
ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
How Much Upside is Left in ANI (ANIP)? Wall Street Analysts Think 41.71%
ANI (ANIP) Upgraded to Strong Buy: Here's Why
New Strong Buy Stocks for April 16th
CGON Stock Up 60.8% in Six Months: Here's What You Need to Know
Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results
Zacks.com featured highlights include Intuit, ANI Pharmaceuticals and Gaming and Leisure Properties
Is American Well (AMWL) Outperforming Other Medical Stocks This Year?
Insmed Ends Brinsupri Development in Skin Disease Post Study Failure
3 Best Earnings Acceleration Stocks to Buy Now for April 2026
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock
AMGN's Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Aberdeen Group plc
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome
7,619 Shares in ANI Pharmaceuticals, Inc. $ANIP Acquired by Ellsworth Advisors LLC
Janux Therapeutics Secures $35M Milestone Payment From BMY Deal
OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus